Announcements Trials

Browse Landscape

Phase

Status

Recruiting 4 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 473 Carcinoma, Non-Small-Cell Lung 447 Breast Neoplasms 331 Neoplasm Metastasis 242 Colorectal Neoplasms 214 Melanoma 213 Leukemia, Myeloid, Acute 191 Multiple Myeloma 180 Recurrence 169 Ovarian Neoplasms 169 Prostatic Neoplasms 163 Lymphoma, Non-Hodgkin 148 Lung Neoplasms 134 Pancreatic Neoplasms 125 Lymphoma 123 Carcinoma, Renal Cell 112 Squamous Cell Carcinoma of Head and Neck 110 Leukemia, Lymphocytic, Chronic, B-Cell 110 Stomach Neoplasms 92 Carcinoma, Hepatocellular 89 Lymphoma, Large B-Cell, Diffuse 88 Leukemia 87 Triple Negative Breast Neoplasms 86 Lymphoma, Follicular 82 Head and Neck Neoplasms 79 Glioblastoma 74 Myelodysplastic Syndromes 70 Urinary Bladder Neoplasms 68 Small Cell Lung Carcinoma 64 Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Solid Cancer × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡